Log in
Enquire now
Centivax

Centivax

Centivax is a San Francisco-based vaccine, therapeutics, and biotechnology company which spun out of Distributed Bio and their internal incubated technology projects headed under the name Centivax.

OverviewStructured DataIssuesContributors

Contents

centivax.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biology
Biology
Vaccine
Vaccine
‌
Snake antivenom
Therapeutics
Therapeutics
Biotechnology
Biotechnology
Healthcare
Healthcare
Technology
Technology
Location
South San Francisco, California
South San Francisco, California
0
San Francisco
San Francisco
United States
United States
B2X
B2B
B2B
CEO
Jacob Glanville
Jacob Glanville
0
Founder
Jacob Glanville
Jacob Glanville
0
Parent Organization
Distributed Bio Inc
Distributed Bio Inc
Date Incorporated
2019
Spun Out From
Distributed Bio Inc
Distributed Bio Inc
Number of Employees (Ranges)
11 – 50
Email Address
info@centivax.com0
Full Address
201 Gateway Boulevard South San Francisco, CA 94080
329 Oyster Point Boulevard, 3rd Floor South San Francisco, CA 940800
Investors
Kendall Capital
Kendall Capital
Base4
Base4
NFX
NFX
Bold Capital Partners
Bold Capital Partners
‌
Amplify Bio
Future Ventures
Future Ventures
DUNS Number
117471125
Founded Date
January 2021
Total Funding Amount (USD)
45,000,000
Latest Funding Round Date
July 9, 2025
Business Model
Commerce
CTO
‌
Nicholas Bayless
0
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
6
COO
David Tsao
David Tsao
0
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
45,000,000

Centivax is a therapeutics company founded to treat and eradicate the remaining pathogens of the 21st century. Centivax was spun out of a series of internally incubated technology projects run at Distributed Bio. Centivax and their CEO Jacob Glanville were featured in the Netflix documentary series "Pandemic," talking about their vaccine technology.

History

Centivax began at Distributed Bio as a vaccine for mutating and naturally polymorphic pathogens of HIV, influenza, Chagas disease, sleeping sickness, Dengue, and Zika. Distributed Bio developed Centivax, an epitope focusing technology that focused the immune response against conserved parts of pathogens that cannot mutate, offering a Universal Vaccine design.

In two repeat studies in sus scrofa (pig) in Distributed Bio's animal facility, the epitope focusing vaccine induced antibodies against 39 viral strains of influenza spanning the last century, including all pandemic events (1918 H1N1 Spanish flu, 1957 H2N2 Asian flu, 1968 H3N2 Hong Kong flu, 1977 H1N1 Russian flu, 2002 H3N2 Fujian flu, and 2009 H1N1 Swine flu).

In a Centivax vaccine designed using only pre-2009 viral strain information, the vaccine further elicited broad neutralizing immunity against future pandemic and seasonal viral strains. Observation of an inverse-dose response, single antigen tests, and 159 monoclonal pig antibodies recovered from immunized animals further clarify the mechanism of epitope focusing by Centivax.

Monoclonals - SARS-CoV-2

Centivax is engineering monoclonal therapeutics against pathogens through computationally guided antibody discovery. This program is part of their response to SARS-CoV-2 (COVID-19), through which they have used the Distributed Bio SuperHuman 2.0 antibody discovery technology and the Tumbler computational antibody optimization technology to discover thousands of antibodies against a novel virus in nine weeks.

Vaccine

Centivax's work in vaccines includes the work done with Distributed Bio on their epitope-focusing technology to guide the immune response against conserved parts of pathogens that cannot mutate. Centivax's flu vaccine is supported by the Bill and Melinda Gates Foundation and featured on Netflix's Pandemic: How to Prevent an Outbreak.

Oligoclonals

Centivax's oligoclonals use a mixture of two or more monoclonal antibodies for when multiple proteins need to be targeted, such as multiple toxins from a bacteria or in snake venom. Their broad-spectrum antivenom is supported by the National Institutes of Health, through which Centivax is developing a human, broadly neutralizing oligoclonal antivenom. Centivax's antibiotic oligoclonals are supported by MTEC and the NMRC in which they are developing a human, broadly neutralizing oligoclonal antibiotic to neutralize viral factors and toxins secreted by common wounds and sepsis causing bacterium.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

Chafing Against Regulation, Silicon Valley Pivots to Pandemic

Andrew Leonard

https://www.wired.com/story/chafing-against-regulation-silicon-valley-pivots-to-pandemic/

Web

April 15, 2020

COVID-19 Research Update Livestream: Dr. Jacob Glanville and Sarah Ives

https://www.youtube.com/watch?v=-sHcWPUrc18

Web

April 10, 2020

Searching for the Cure

Dr. Phil Staff

https://www.drphil.com/shows/searching-for-the-cure/

Web

April 22, 2020

The Synthetic Biology Companies Racing To Fight Coronavirus

John Cumbers

https://www.forbes.com/sites/johncumbers/2020/02/05/seven-synthetic-biology-companies-in-the-fight-against-coronavirus/#e8dc4c316ef4

Web

February 5, 2020

Who is Jacob Glanville? Netflix Pandemic Doctor has found five antibodies that could be injected to neutralize Coronavirus COVID 19

https://www.ibtimes.sg/who-jacob-glanville-netflix-pandemic-doctor-has-found-five-antibodies-that-could-be-injected-42180

Web

April 1, 2020

References

Find more companies like Centivax

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.